FDA 483 - Bell-More Labs, Inc. - June 07, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bell-More Laboratories Inc. in Hampstead, MD, revealed significant deficiencies across its manufacturing and quality control operations. The firm failed to maintain adequate aseptic processing conditions, environmental monitoring, and cleaning validations. Furthermore, issues were identified with data integrity, equipment maintenance, process validations, and the overall effectiveness of the quality control unit, indicating systemic failures in ensuring drug product quality and sterility.
ID · 32996a1a-9ceb-486d-b1f7-2b59bfadbacf